Katsunori Ikari

Oct 16, 2024 | medrxiv.org | Suguru Honda |Katsunori Ikari |Eiichi Tanaka |Mayuko Fujisaki

Competing interestsS.H. and M.F. declares no conflicts of interest. K.I. has received speakers fee from Asahi Kasei Pharma Co., Astellas Pharma Inc., AbbVie Japan GK, Ayumi Pharmaceutical Corporation, Bristol Myers Squibb Co., Ltd., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., Janssen Pharmaceutical K.K., Kaken Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Co., Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd., Teijin Pharma Ltd, and UCB Japan Co. Ltd.

Sep 13, 2024 | medrxiv.org | Yuki Ishikawa |Katsunori Ikari |Suguru Honda |Shunsuke Uchiyama

S.U., Y.I., K.I., S.H., K.H., E.T., and C.T. have no conflicts of interest. Y.K. has research grants from Takeda Pharmaceuticals. T.G. received speaking fees from Asahi Kasei Pharma, Astellas, Boehringer-Ingelheim, Bristol-Myers Squibb, Chugai, Eisai, Eli Lily, Gilead Sciences, Ono Pharmaceuticals, Pfizer, and Tanabe Mitsubishi. G.G. declared competing interests, and patent application PCT/WO2019/079493 has been filed for the mosaic chromosomal alteration detection method used in this study.